iTonic Holdings Ltd. (ITOC)
NasdaqCM
Price as at 1 Oct 2026, 08:23 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
iTonic Holdings Ltd. trades at $0.28. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About iTonic Holdings Ltd.
iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. The company's proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients. The company was formerly known as Pheton Holdings Ltd and changed its name to iTonic Holdings Ltd. in January 2026. iTonic Holdings Ltd. was founded in 1998 and is headquartered in Beijing, China. iTonic Holdings Ltd. operates as a subsidiary of ZJW (BVI) LTD.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its ITOC data?
Fundamentals for ITOC come from company filings and exchange data, as listed on NasdaqCM; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 08:23 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ITOC, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.